Search

Your search keyword '"Bahmad, Hisham F."' showing total 306 results
Start Over Author "Bahmad, Hisham F."
306 results on '"Bahmad, Hisham F."'

11. Gestational Trophoblastic Disease: Complete versus Partial Hydatidiform Moles.

Author

Gonzalez, Jeffrey, Popp, Meagan, Ocejo, Stephanie, Abreu, Alvaro, Bahmad, Hisham F., and Poppiti, Robert

Subjects
GESTATIONAL trophoblastic disease, MOLAR pregnancy, CYCLIN-dependent kinase inhibitors, CHORIOCARCINOMA, GENOMIC imprinting
Abstract

Hydatidiform moles, including both complete and partial moles, constitute a subset of gestational trophoblastic diseases characterized by abnormal fertilization resulting in villous hydrops and trophoblastic hyperplasia with or without embryonic development. This involves chromosomal abnormalities, where one or two sperms fertilize an empty oocyte (complete hydatidiform mole (CHM); mostly 46,XX) or two sperms fertilize one oocyte (partial hydatidiform mole (PHM); mostly 69,XXY). Notably, recurrent occurrences are associated with abnormal genomic imprinting of maternal effect genes such as NLRP7 (chromosome 19q13.4) and KHDC3L (chromosome 6q1). Ongoing efforts to enhance identification methods have led to the identification of growth-specific markers, including p57 (cyclin-dependent kinase inhibitor 1C; CDKN1C), which shows intact nuclear expression in the villous cytotrophoblast and villous stromal cells in PHMs and loss of expression in CHMs. Treatment of hydatidiform moles includes dilation and curettage for uterine evacuation of the molar pregnancy followed by surveillance of human chorionic gonadotropin (HCG) levels to confirm disease resolution and rule out the development of any gestational trophoblastic neoplasia. In this review, we provide a synopsis of the existing literature on hydatidiform moles, their diagnosis, histopathologic features, and management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer.

Author

Alhajahjeh, Abdulrahman, Al-Faouri, Raad, Bahmad, Hisham F., Bader, Taima', Dobbs, Ryan W., Abdulelah, Ahmed A., Abou-Kheir, Wassim, Davicioni, Elai, Lee, David I., and Shahait, Mohammed

Subjects
GLUCAGON-like peptide-1 agonists, METFORMIN, RADIOTHERAPY, THYROID gland tumors, CELL proliferation, ONCOLOGY, HYPOGLYCEMIC agents, PROSTATE tumors, CELLULAR signal transduction, EVALUATION of medical care, TRANSLATIONAL research, DIABETES
Abstract

Simple Summary: In this review paper, we outline the role of GLP-1-RAs in potentially influencing PCa development and progression. While GLP-1-RAs show promise in inhibiting cancer cell proliferation, particularly when combined with metformin or radiotherapy, clinical data on their impact on PCa outcomes are limited. Future research should focus on dedicated trials to evaluate GLP-1-RA's role in PCa management, including its potential as a prophylactic treatment and adjunct therapy in various PCa stages. Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells. We discuss the potential pathways involving cAMP, ERK, AMPK, mTOR, and P27. Furthermore, we underscore the imperative for additional research to elucidate the impact of GLP-1-RA treatment on PCa progression, patient outcomes, and potential interactions with existing therapies. Translational studies and clinical trials are crucial for a comprehensive understanding of the role of GLP-1-RA in PCa management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Unraveling the Mysteries of Perineural Invasion in Benign and Malignant Conditions

Author

Bahmad, Hisham F., primary, Gogola, Samantha, additional, Rejzer, Michael, additional, Stoyanov, Kalin, additional, Gomez, Aaron S., additional, Valencia, Ann-Katrin, additional, Cummings, Adonicah, additional, Skerry, Timothy, additional, Alloush, Ferial, additional, Aljamal, Abed A., additional, Deb, Arunima, additional, Alghamdi, Sarah, additional, and Poppiti, Robert, additional

Published
2023
Full Text
View/download PDF

37. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.

Author

Bahmad, Hisham F., Oh, Kei Shing, and Alexis, John

Subjects
*NEVUS, *MELANOMA, *P16 gene, *IMMUNOSTAINING, *IMMUNOHISTOCHEMISTRY, *SURGICAL excision, *DATABASES
Abstract

Background: PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi. Methods: This is a single‐center retrospective cohort analysis over a 4‐year period (2017–2020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16. Results: Most malignant melanomas showed positive/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+/p16− melanocytic lesion is unlikely to be a nevus where most nevi were PRAME−/p16+. Conclusion: In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Squamous cell carcinoma arising in a Zenker diverticulum

Author

Polit, Francesca, primary, Bahmad, Hisham F, additional, Wahi, Jessica, additional, Deb, Arunima, additional, Newsome, Kevin, additional, Howard, Lydia, additional, Poppiti, Robert, additional, Ben-David, Kfir, additional, and Alghamdi, Sarah, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results